Abstract
Drug metabolizing enzymes and transporters are increasingly recognized as key determinants of the inter-individual variability in pharmacokinetic (PK) and pharmacodynamic (PD) outcomes of clinically important drugs. To date, most studies investigating this variability have focused on polymorphisms (e.g. SNPs) in the genes encoding metabolic enzymes and transporters; however, it has recently been reported that the expression of some of these genes is under the control of epigenetic mechanisms. The most common epigenetic mechanism of mammalian genome regulation is DNA methylation, which does not change the genetic code but affects gene expression. Owing to its maintenance of the genomic sequence, DNA methylation is expected to offer an explanation for the controversial phenotypes of certain genetic polymorphisms. It has been recognized that DNA methylation plays a role in the transcriptional regulation of some PK/PD genes. In this review, we describe the impact of various epigenetic mechanisms, especially DNA methylation, on the expression (or activity) of drug metabolizing enzymes and transporter genes.
Keywords: Epigenetics, methylation, histone acetylation, allelic expression imbalance
Current Drug Metabolism
Title: Epigenetic Regulation of Genes Encoding Drug-Metabolizing Enzymes and Transporters; DNA Methylation and Other Mechanisms
Volume: 9 Issue: 1
Author(s): Ichiro Ieiri, Takeshi Hirota, Hiroshi Takane and Shun Higuchi
Affiliation:
Keywords: Epigenetics, methylation, histone acetylation, allelic expression imbalance
Abstract: Drug metabolizing enzymes and transporters are increasingly recognized as key determinants of the inter-individual variability in pharmacokinetic (PK) and pharmacodynamic (PD) outcomes of clinically important drugs. To date, most studies investigating this variability have focused on polymorphisms (e.g. SNPs) in the genes encoding metabolic enzymes and transporters; however, it has recently been reported that the expression of some of these genes is under the control of epigenetic mechanisms. The most common epigenetic mechanism of mammalian genome regulation is DNA methylation, which does not change the genetic code but affects gene expression. Owing to its maintenance of the genomic sequence, DNA methylation is expected to offer an explanation for the controversial phenotypes of certain genetic polymorphisms. It has been recognized that DNA methylation plays a role in the transcriptional regulation of some PK/PD genes. In this review, we describe the impact of various epigenetic mechanisms, especially DNA methylation, on the expression (or activity) of drug metabolizing enzymes and transporter genes.
Export Options
About this article
Cite this article as:
Ieiri Ichiro, Hirota Takeshi, Takane Hiroshi and Higuchi Shun, Epigenetic Regulation of Genes Encoding Drug-Metabolizing Enzymes and Transporters; DNA Methylation and Other Mechanisms, Current Drug Metabolism 2008; 9 (1) . https://dx.doi.org/10.2174/138920008783331130
DOI https://dx.doi.org/10.2174/138920008783331130 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Combined Therapy for Gastrointestinal Carcinomas: Exploiting Synergies Between Gene Therapy and Classical Chemo-Radiotherapy
Current Gene Therapy Chemosensitization and Immunosensitization of Resistant Cancer Cells to Apoptosis and Inhibition of Metastasis by the Specific NF-κB Inhibitor DHMEQ
Current Pharmaceutical Design Physiologically Based Mathematical Models to Optimize Therapies Against Metastatic Colorectal Cancer: A Mini-Review
Current Pharmaceutical Design Bispecific Antibodies (bsAbs): Promising Immunotherapeutic Agents for Cancer Therapy
Protein & Peptide Letters Intracellular Bioinorganic Chemistry and Cross Talk Among Different -Omics
Current Topics in Medicinal Chemistry Reduced Lipocalin 2 Expression Contributes to Vincristine Resistance in Human Colon Cancer Cells
Recent Patents on Anti-Cancer Drug Discovery HOX Genes as Potential Markers of Circulating Tumour Cells
Current Molecular Medicine Antiangiogenic Agents: Studies on Fumagillin and Curcumin Analogs
Current Pharmaceutical Design Diallyl Sulfide: Potential Use in Novel Therapeutic Interventions in Alcohol, Drugs, and Disease Mediated Cellular Toxicity by Targeting Cytochrome P450 2E1
Current Drug Metabolism Antiangiogenic Therapy and Ovarian Cancer
Current Women`s Health Reviews Prostaglandin J2 Family and the Cardiovascular System
Current Vascular Pharmacology Chemoprevention of Cancers in Gastrointestinal Tract with Cyclooxygenase 2 Inhibitors
Current Pharmaceutical Design Genistein: A Boon for Mitigating Ischemic Stroke
Current Topics in Medicinal Chemistry Src Family Kinases: Potential Targets for the Treatment of Human Cancer and Leukemia
Current Pharmaceutical Design Potential Role of MEK Inhibition in Treating Patients with Colorectal Cancer
Current Cancer Therapy Reviews Receptor Tryosine Kinase Inhibitors as Potent Weapons in War Against Cancers
Current Pharmaceutical Design Targeting Inflammatory Bowel Diseases by Nanocarriers Loaded with Small and Biopharmaceutical Anti-Inflammatory Drugs
Current Pharmaceutical Design Is 5-ASA Still the Treatment of Choice for Ulcerative Colitis?
Current Drug Targets The Design and Characterization of a Novel beta-casein Nano-vehicle Loaded with Platinum Anticancer Drug for Drug Delivery
Anti-Cancer Agents in Medicinal Chemistry Neurodevelopment in Schizophrenia: The Role of the Wnt Pathways
Current Neuropharmacology